Insights from recent industry events clear path for companies to identify how their internal practices could be harming the environment.
Earlier in the year, I wrote about efforts afoot to reduce the carbon footprint of clinical trials. In regard to sustainability and the environment, however, this is not a one-and-done solution. In fact, most pharmaceutical companies find it difficult to know where to start when addressing their internal practices that negatively impact the environment, but starting with CO2 emissions is a good beginning.
To that end, Janssen’s Clinical Innovation Team presented its own carbon footprint contributors at the Clinical Trials Europe 2022 Informa event six months ago, with the following results from a recent Phase I trial, reflecting share of CO2 emissions: patient journey, 30.8%; trial site utilities, 15.5%; Janssen staff commuting, 14.6%; patient accommodation, 11.8%; Janssen facility utilities, 7.5%; trial site staff commuting, 5.2%; testing kits, 5.2%; drug product, 4.7%; samples, 4.6%; external meetings, .1%.
It is this ability to measure and quantify that companies can initiate their journey for change with informed benchmarks. Such is the goal of the Pistoia Alliance’s Clinical Trial Environmental Impact Community of Interest, launched in mid-October 2022. According to its website, the goal is to identify key drivers for carbon footprint in a clinical trial, develop metrics with estimates of each for a “typical” clinical trial, and then users of this dynamic model will be able to turn on and off key parameters, such as patient engagement, decentralized clinical trials (DCTs), and patient diversity activities in order to see the impact of each on carbon footprint.
This ability to turn on and off parameters makes it important to understand the unintended consequences of choices. For example, while DCTs may be desirable from a “patient journey” aspect of getting to and from a site, the downstream effect of drug delivery to the home could include emissions in the form of transportation, as well as eco-insufficient packaging choices.
At the Pharma 2023 Reuters event in April, a panel discussed this very conundrum. With the focus on climate change, one expert warned “If we change something, we need to ensure that we are not going to degrade the environment in another way.”
Panelists also discussed where companies should start their efforts, and all agreed: it starts with commitment, collective action, and a collaborative effort to share progress and standards.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.